<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01072955</url>
  </required_header>
  <id_info>
    <org_study_id>HEPSBCCV1109BOV_EUR</org_study_id>
    <secondary_id>version 2</secondary_id>
    <nct_id>NCT01072955</nct_id>
  </id_info>
  <brief_title>Efficacy And Safety Of Heparin In Patients With Cardiovascular Surgery Using Cardiopulmonary Bypass</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azidus Brasil</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azidus Brasil</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to verify, through a randomized, blinded, parallel
      clinical trial, the efficacy of bovine heparin from Eurofarma Laboratory product when
      compared to porcine heparin APP Pharmaceutical in patients undergoing surgery cardiovascular
      disease and who require cardiopulmonary bypass, through the control of hemostasis during and
      after surgery, based on measurements of markers of coagulation ACT, aPTT, anti-Xa heparin
      levels and the excessive blood loss (hemorrhage) after the end of surgery.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2010</start_date>
  <completion_date type="Anticipated">October 2011</completion_date>
  <primary_completion_date type="Anticipated">August 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Coagulometric parameters markers heparin activity: ACT, APTT and Anti - Xa</measure>
    <time_frame>(T0) Pre heparintion; (T1) Top of extracorporeal; (T2) Intraoperative period; (T3) End bypass; (T4) Postoperative</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Value of the total dose of heparin used, the activity and adequate reversal with the use of protamine.</measure>
    <time_frame>(T0) Pre heparintion; (T1) Top of extracorporeal; (T2) Intraoperative period; (T3) End bypass; (T4) Postoperative</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Prevention of Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>heparin of bovine origin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5.000UI/mL bottle with 5mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>heparin of porcine origin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5000 USP Heparin Units / mL vial with 10 mL vial</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bovine Heparin</intervention_name>
    <description>5.000UI/mL bottle with 5mL</description>
    <arm_group_label>heparin of bovine origin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Porcine heparin</intervention_name>
    <description>5000 USP Heparin Units / mL vial with 10 mL vial</description>
    <arm_group_label>heparin of porcine origin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who agree with all aspects of the study and sign the FICT;

          -  Patients of both sexes;

          -  Patients over the age of 18 years;

          -  Patients with indication for cardiac surgery requiring cardiopulmonary bypass.

        Exclusion Criteria:

          -  Patients with hematological disorders that compromise the surgical outcome (eg,
             myeloproliferative disorders, anemia, Hb &lt;11.0 g / dL, platelets &lt;100,000 mm3);

          -  Patients with disorders of hemostasis (INR&gt; 1.40) (APTTr&gt; 1.40);

          -  Patients with renal impairment (creatinine&gt; 1.50);

          -  Patients with deep hyperthermia;

          -  Liver disease (AST and ALT&gt; 2 times that of the reference value);

          -  Patients with a history of allergy to heparin or protamine;

          -  Patients with a history of heparin-induced thrombocytopenia;

          -  infection (eg endocarditis, septicemia and pneumonia);

          -  Reoperations;

          -  Use of antiplatelet agents (clopidogrel and ticlopidine) for less than 7 days;

          -  Use of aspirin for less than 5 days;

          -  Use of heparin, low molecular weight less than 24 hours;

          -  Use of unfractionated heparin for less than 12 hours.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alexandre Frederico, Dr.</last_name>
    <phone>+551938293822</phone>
    <email>alexandre@lalclinica.com.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>LAL Clinica Pesquisa e Desenvolvimento Ltda</name>
      <address>
        <city>Valinhos</city>
        <state>SÃ£o Paulo</state>
        <zip>13276-245</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karina Guerra</last_name>
      <phone>+551938293822</phone>
      <email>karina@lalclinica.com.br</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2010</study_first_submitted>
  <study_first_submitted_qc>February 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2010</study_first_posted>
  <last_update_submitted>January 27, 2011</last_update_submitted>
  <last_update_submitted_qc>January 27, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Alexandre Frederico</name_title>
    <organization>LAL Clinica</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

